Aripiprazole, also known by its trade name Abilify Discmelt®, is an atypical antipsychotic medication that is utilized in the treatment of a diverse range of mood and psychotic disorders, including but not limited to schizophrenia, bipolar I disorder, major depressive disorder, irritability linked with autism, and Tourette's syndrome. This medication functions through its mechanism of action as both a 5-HT2A agonist and a D2 receptor agonist. Aripiprazole was first approved by the US FDA in 2002, with Otsuka Holdings as the pharmaceutical company responsible for its development. Its primary indication is for the treatment of schizophrenia. Click on the image below to begin the exploration journey of Aripiprazole through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!